Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 | Q12908 | 12/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | FABP3 | P05413 | 1/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22286570 | 0.97 | SLC10A2 (0.37) | SLC10A2NR1H4FABP3S1PR5CYP2C19 | |
| SCHEMBL30611635 | 0.92 | SLC10A2 (0.43) | SLC10A2NR1H4 | |
| SCHEMBL22286643 | 0.92 | SLC10A2 (0.43) | SLC10A2NR1H4 | |
| SCHEMBL22286487 | 0.92 | SLC10A2 (0.43) | SLC10A2NR1H4 | |
| SCHEMBL5223154 | 0.92 | SLC10A2 (0.43) | SLC10A2NR1H4 | |
| SCHEMBL30540746 | 0.92 | SLC10A2 (0.43) | SLC10A2NR1H4 | |
| SCHEMBL23375168 | 0.92 | SLC10A2 (0.40) | SLC10A2NR1H4LMNANPSR1 | |
| SCHEMBL22286431 | 0.90 | SLC10A2 (0.46) | SLC10A2NR1H4LMNA | |
| SCHEMBL22286359 | 0.90 | SLC10A2 (0.40) | SLC10A2NR1H4FABP3S1PR5CYP2C19 | |
| SCHEMBL22286481 | 0.89 | SLC10A2 (0.37) | SLC10A2NR1H4S1PR5CYP2C19LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773071-B2 | Benzothiazepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2023-10-03 | — | — | US | claimed |
| EP-3921027-B1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2023-07-19 | — | — | EP | claimed |
| EP-3921027-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | Albireo AB (SE) | 2021-12-15 | — | — | EP | claimed |
| US-10975045-B2 | Benzothiazepine compounds and their use as bile acid modulators | Aibireo AB (SE) | 2021-04-13 | — | — | US | claimed |
| WO-2020161216-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2020-08-13 | — | — | WO | claimed |
| US-20200247768-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2020-08-06 | — | — | US | claimed |
| US-20240207286-A1 | ASBT INHIBITORS IN THE TREATMENT OF RENAL DISEASES | ALBIREO AB (SE) | 2024-06-27 | — | — | US | disclosed |
| WO-2024121434-A1 | ASBT INHIBITORS IN THE TREATMENT OF RENAL DISEASES | ALBIREO AB (SE) | 2024-06-13 | — | — | WO | disclosed |
| US-20230338392-A1 | SUBCUTANEOUS ADMINISTRATION OF AN ASBT INHIBITOR | ALBIREO AB (SE) | 2023-10-26 | — | — | US | disclosed |
| WO-2023203248-A1 | SUBCUTANEOUS ADMINISTRATION OF AN ASBT INHIBITOR | ALBIREO AB (SE) | 2023-10-26 | — | — | WO | disclosed |
| US-11773071-B2 | Benzothiazepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2023-10-03 | — | — | US | disclosed |
| EP-3921027-B1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2023-07-19 | — | — | EP | disclosed |
| EP-3921027-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | Albireo AB (SE) | 2021-12-15 | — | — | EP | disclosed |
| US-20210147372-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2021-05-20 | — | — | US | disclosed |
| US-10975045-B2 | Benzothiazepine compounds and their use as bile acid modulators | Aibireo AB (SE) | 2021-04-13 | — | — | US | disclosed |
| WO-2020161216-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2020-08-13 | — | — | WO | disclosed |
| US-20200247768-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773071-B2 | Benzothiazepine compounds and their use as bile acid modulators | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885NR1H4 6/4885FABP3 65/4885 |
| US-20200247768-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885NR1H4 6/4885FABP3 65/4885 |
| US-20230338392-A1 | SUBCUTANEOUS ADMINISTRATION OF AN ASBT INHIBITOR | SLC10A1, SLC10A2, SLC10A6 | SLC10A2 2/4885NR1H4 5/4885FABP3 243/4885 |
| US-20210147372-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885NR1H4 6/4885FABP3 65/4885 |
| US-10975045-B2 | Benzothiazepine compounds and their use as bile acid modulators | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885NR1H4 6/4885FABP3 65/4885 |
| US-20240207286-A1 | ASBT INHIBITORS IN THE TREATMENT OF RENAL DISEASES | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885NR1H4 5/4885FABP3 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.